Timentin is a medicine containing the active ingredient(s) ticarcillin + clavulanic acid. On this page you will find out more about Timentin, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: ticarcillin + clavulanic acid
Information for medicine and pack size:
Timentin powder for injection, 10 x 3.1 g vials
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
TIMENTIN is indicated in the treatment of serious infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: Septicaemia (and bacteraemia) cases caused by beta-lactamase producing organisms including strains of Klebsiella pneumoniae, E.coli, Staphylococcus aureus and Pseudomonas aeruginosa. Lower Respiratory Infections cases caused by beta-lactamase producing susceptible organisms including strains of Staphylococcus aureus, Haemophilus influenzae and Klebsiella pneumoniae. Bone and Joint Infections cases caused by beta-lactamase producing susceptible organisms including strains of Staphylococcus aureus. Skin and Skin Structure Infections cases caused by beta-lactamase producing susceptible organisms including strains of Staphylococcus aureus, Klebsiella pneumoniae and E. coli. Urinary Tract Infections cases caused by beta-lactamase producing susceptible organisms including strains of E.coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus. Gynaecological Infections including cases caused by beta-lactamase producing susceptible organisms including strains of Klebsiella pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis. While TIMENTIN is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by ticarcillin susceptible and beta-lactamase producing ticarcillin resistant organisms. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to TIMENTIN. Therapy with TIMENTIN may, however, be initiated before results of such tests are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued. Based on the in vitro synergism between ticarcillin and gentamicin sulphate/tobramycin sulphate/amikacin sulphate against certain strains of Pseudomonas aeruginosa, combined therapy has been successful. TIMENTIN may be used as combination therapy concurrently with the aminoglycosides but both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. Results of susceptibility tests showing synergy between ticarcillin and one aminoglycoside should not be extrapolated to combination with another aminoglycoside. Prophylactic Use: TIMENTIN may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing abdominal hysterectomy or elective colorectal surgery when there is a significant risk of surgery related postoperative infections. If signs of postsurgical infection should appear, these should be treated with appropriate therapy.
Table of characteristics
|Visual appearance||A fine white powder|
|Dosage Form||Injection, powder for|
|Route of administration||Intravenous|
10 vials: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||18 Months|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Timentin | myVMC
Timentin is a bactericidal medicine containing potassium clavulanate and ticarcillin sodium. It is used to treat respiratory and other infections.
Read more on myVMC – Virtual Medical Centre website
Timentin Powder for infusion - myDr.com.au
Timentin Powder for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 0 results